Prevalence of anal fistulas: a systematic review and meta-analysis

Arash Sarveazad1,2, Mansour Bahardoust1,3, Jебreil Shamseddin4, Mahmoud Yousefifard5
1Colorectal Research Center, Iran University of Medical Sciences, Tehran, Iran
2Nursing Care Research Center, Iran University of Medical Sciences, Tehran, Iran
3Department of Epidemiology, School of Public Health, Shahid Beheshti University of Medical Sciences, Tehran, Iran
4Infectious and Tropical Diseases Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran
5Physiology Research Center, Iran University of Medical Sciences, Tehran, Iran

ABSTRACT
Analy fistula refers to a clinical condition with local pain and inflammation associated with purulent discharge that affects the quality of life. Due to the lack of studies, the presence of bias, and high heterogeneity in the studies, the present systematic review is the first to be performed on the population-based database in this field. The present systematic review and meta-analysis was performed according to MOOSE guidelines. After systematic searching in electronic databases, only four articles met the inclusion criteria. After preparing a checklist and extracting data from the relevant articles, a meta-analysis was performed. All studies on the prevalence of anal fistula are related to Europe, and so far, no study has been conducted on other continents. The overall prevalence of anal fistula in European countries was 18.37 (95% CI: 18.20-18.55%) per 100,000 individuals, and the highest prevalence was reported for Italy (23.20 (95% CI: 22.82 to 23.59) per 100,000 people). From the present population-based (224,097,362) study results, it can be concluded that there is a prominent knowledge gap in this context. Because all the studies included in the current study relate only to Europe, the need for further research in this field in other countries is inevitably sensible.

Keywords: Anal Fistulas, Prevalence, Systematic Review.
(Please cite as: Sarveazad A, Bahardoust M, Shamseddin J, Yousefifard M. Prevalence of anal fistulas: a systematic review and meta-analysis. Gastroenterol Hepatol Bed Bench 2022;15(1):1-8).

Introduction

Anal fistula refers to a clinical condition with local pain and inflammation associated with purulent discharge that affects the quality of life (1). Most perineal abscesses originate in one of the anal glands. Obstruction of these glands causes bacterial overgrowth and, eventually, abscesses that settle in the space between the sphincters (external and internal anal sphincter) (2). These abscesses go through several exit routes. Most of them descend to the anoderm (perineal abscesses) or pass through the thickness of the external anal sphincter and end up in the ischiorectal space. A small number end up in the suprapelvis space. When an abscess is drained, either spontaneously or surgically, the infection's drainage route remains and is lined with epithelial tissue, leading to the formation of anal fistulas. About 60% of these abscesses lead to such a fate (3). Finally, a granular duct forms between the anorectal region and the perineal region. 1.2 to 2.8 of every 10,000 people develop anal fistula (4). A typical fistula consists of a primary (internal) and a secondary (external) orifice. Still, in some cases, the duct may become blocked along its path and a sinus remain, so perineal sinuses should be considered as a type of perianal fistula (5). Anal fistula treatment currently includes a combination of medication and surgery to control pain, prevent secondary infections and discharge, and improve the patient's quality of life (6). Epidemiological data on the prevalence of anal fistula is essential for optimal policy-making to achieve the
most effective scientific methods for controlling and treating this problem. Few studies have been done on the prevalence of anal fistula in different populations globally, and the results of these few studies are contradictory. The small number of studies, the presence of bias, and the high heterogeneity in the studies prevent scientists from providing a definitive conclusion regarding the prevalence of anal fistula. Therefore, this study aimed to investigate the prevalence of anal fistulas through a systematic review and meta-analysis approach.

Methods

Study design

The present meta-analysis was designed to summarize studies conducted on humans to evaluate the prevalence of anal fistula using the MOOSE guidelines for systematic review and meta-analysis in observational research (7). An extensive search of the electronic databases Medline, Embase, CINHAL, Scopus, and Web of Sciences was conducted by the end of June 2020.

PICO definition

The problem or population (P) of the study was human society, factor (I) was anal fistula, and the outcome (O) was the prevalence of anal fistula. Comparison (C) was not applicable in this study.

Search strategy

To achieve the present study’s objectives, an extensive search of electronic databases and the references of related articles was conducted. A gray literature search was also done in the present study. The search strategy was based on keywords related to anal fistula, and the process of how to search and summarize data has been reported in previous meta-analyses (8-16). The Medline (PubMed) search strategy as a template is as follows:

1. "Rectal Fistula"(Mesh) OR Rectal Fistula(tiab) OR Fistula, Rectal(tiab) OR Anal Fistula(tiab) OR anus fistula(tiab) OR anal fistula(tiab) OR anal fistule(tiab) OR fistula ani(tiab) OR perianal fistula(tiab) OR Fistula-in-ano(tiab)
2. “Prevalence”(Mesh) OR “Epidemiology”(Mesh) OR “Incidence”(Mesh) OR Prevalence(tiab) OR Epidemiology(tiab) OR Incidence(tiab) OR incidence rate(tiab) OR rate, incidence(tiab) OR epidemiologic(tiab)
3. #1 AND #2

Inclusion and exclusion criteria

The present study's inclusion criteria included observational studies performed on a human population without age, sex, or racial restrictions. Analyses performed on the general population were included. The prevalence of anal fistula was reported in positive cases in a specific population (for example, 10,000 people). Any study performed in a clinic or hospital or on a particular disease, such as Crohn's disease, trauma, postoperative fistula, and postpartum fistula, was excluded, because the prevalence reported in these

| Table 1. Key questions and NHLBI quality control tool items |
|-----------------------------------------------------------|
| 1. Was the research question or objective in this paper clearly stated? |
| 2. Was the study population specified and defined? |
| 3. Was the participation rate of eligible persons at least 50%? |
| 4. Were all the subjects selected or recruited from the same or similar populations (including the same period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? |
| 5. Was a sample size justification, power description, or variance and effect estimates provided? |
| 6. For the analyses in this paper, were the exposure(s) of interest measured before the outcome(s) being measured? |
| 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? |
| 8. For exposures that can vary in amount or level, did the study examine different exposure levels related to the outcome (e.g., categories of exposure or exposure measured as a continuous variable)? |
| 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? |
| 10. Was the exposure(s) assessed more than once over time? |
| 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? |
| 12. Were the outcome assessors blinded to the exposure status of participants? |
| 13. Was the loss to follow-up after baseline 20% or less? |
| 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? |
studies was falsely high and did not provide actual data on the prevalence of this problem in the general community. Reviews and case reports were also excluded.

**Data Extraction**

Two independent researchers collected the data. After combining the results from the databases in the Endnote program and performing the gray literature search (Google search and Google Scholar), the two researchers performed initial screenings independently. The title and abstract of each article were studied, and if the article was relevant or likely to be related, the full text of the article was reviewed. "The extracted data was then summarized in a checklist designed based on the PRISMA statement guidelines (17) and included information related to the study design, sample characteristics, the number of samples studied, data collection period, country studied, the population covered in the study, age range, and the number of anal fistula cases.

**Quality control of the articles**

Articles were controlled for quality according to NHLBI guidelines (18), a tool containing 14 items for examining the quality of observational articles. Based on the 14 key questions presented below (Table 1), each item received a score of Yes / No / Not applicable / Not reported / cannot be determined. A “YES” score was awarded when the item in the question was clearly and thoroughly explained in the article. If the question was not answered in the article, a “NO” was scored. If no information about the item was reported in the article, it received a “Not reported score,” and if it was not possible to determine an answer based on the available information in the article, a score of “Could not be determined” was assigned. If the item was not applicable to the study, the answer was “Not applicable.”

**Statistical analysis**

Analysis was performed using STATA 14.0 statistical program. All studies were summarized based on the studied outcome, the prevalence of anal fistula in the general population. As some studies reported the number of cases of anal fistula in 10,000 people and some studies reported cases in 100,000 people, the number of cases was reported in 100,000 patients to conveniently perform the meta-analysis. The presence of heterogeneity was investigated using the I² test. Based on the presence or absence of heterogeneity, a random effect model or a fixed-effect model was used to perform the analysis, respectively. Beg’s test and Funnel Plot were used to identify publication bias.

**Results**

**Characteristics of the included studies**

The initial search resulted in 2649 studies. After eliminating duplicates and reading the titles and abstracts of the remaining articles, the full texts of 31 articles were studied in more detail. Eventually, 27 studies were excluded, 17 due to evaluation of the prevalence of anal fistula in patients with Crohn's disease, six due to the prevalence of anal fistula after parturition, three due to the prevalence of anal fistula after surgery, and one for being a review article. Figure 1 shows the selection process of articles in the present study.

**Figure 1. Flowchart of the present study**

The four studies included were all conducted in Europe (4, 19-21). The first study was conducted in Finland between 1969 and 1978. The second study was a 30-center study in continental Europe conducted...
4 Prevalence of anal fistulas

Table 2. Characteristics of the entered studies.

| Study                | Recruitment period | Country            | Population coverage* | Study design          | Age group          | Male number | Number of fistulae |
|----------------------|--------------------|--------------------|----------------------|-----------------------|--------------------|-------------|-------------------|
| Cuschieri; 2001      | 1980-1994          | European countries | 4.60                 | Registry survey       | Newborns           | NR          | 72                |
| Hokkanen; 2019       | 2014 UK            | 4.88               | Registry survey      | Children and adult    | NR                 | 1143        |
|                      | 2015 UK            | 4.22               |                      |                       |                    | 938         |
|                      | 2016 UK            | 3.57               |                      |                       |                    | 688         |
|                      | 2017 UK            | 3.17               |                      |                       |                    | 579         |
| Sainio; 1984         | 1969-1978 Finland  | 0.51               | Retrospective analysis | Children and adult    | 288                | 458         |
| Zanotti; 2007        | 2004 England       | 49.56              | Registry survey      | Children and adult    | NR                 | 9104        |
|                      | 2002 Germany       | 82.54              |                      |                       |                    | 16645       |
|                      | 2002 Italy         | 56.99              |                      |                       |                    | 13231       |
|                      | 2001 Spin          | 14.05              |                      |                       |                    | 1458        |

* Numbers are presented in a million population

Table 3. Quality control of imported articles.

| Item                                                                 | Cuschieri; 2001 | Hokkanen; 2019 | Sainio; 1984 | Zanotti; 2007 |
|---------------------------------------------------------------------|-----------------|----------------|--------------|---------------|
| 1. Was the research question or objective in this paper clearly stated? | Yes             | Yes            | Yes          | Yes           |
| 2. Was the study population specified and defined?                  | Yes             | Yes            | Yes          | Yes           |
| 3. Were the participation rate of eligible persons at least 50%?     | Yes             | Yes            | NR           | Yes           |
| 4. Were all the subjects selected or recruited from the same or similar populations (including the same period)? Were inclusion and exclusion criteria for being in the study prespecified and applied uniformly to all participants? | Yes             | Yes            | Yes          | Yes           |
| 5. Was a sample size justification, power description, or variance and effect estimates provided? | No              | No             | No           | No            |
| 6. For the analyses in this paper, were the exposure(s) of interest measured before the outcome(s) being measured? | NA              | NA             | NA           | NA            |
| 7. Was the timeframe sufficient so that one could reasonably expect to see an association between exposure and outcome if it existed? | Yes             | Yes            | Yes          | Yes           |
| 8. For exposures that can vary in amount or level, did the study examine different exposure levels related to the outcome (e.g., categories of exposure or exposure measured as a continuous variable)? | NA              | NA             | NA           | NA            |
| 9. Were the exposure measures (independent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | Yes             | Yes            | Yes          | Yes           |
| 10. Was the exposure(s) assessed more than once over time?          | NA              | NA             | NA           | NA            |
| 11. Were the outcome measures (dependent variables) clearly defined, valid, reliable, and implemented consistently across all study participants? | Yes             | Yes            | Yes          | Yes           |
| 12. Were the outcome assessors blinded to the exposure status of participants? | No              | No             | No           | No            |
| 13. Was the loss to follow-up after baseline 20% or less?           | NR              | NR             | NR           | NR            |
| 14. Were key potential confounding variables measured and adjusted statistically for their impact on the relationship between exposure(s) and outcome(s)? | NA              | NA             | NA           | NA            |

NA: Not applicable; NR: Not reported

between 1980 and 1994. The third study was a quadrilateral study conducted in Spain (2001), Germany (2002), Italy (2002), and the United Kingdom (2004). The fourth article contained data collected in the UK in 2014, 2015, 2016, and 2017. In the study of Cuschieri et al. in Europe, the prevalence of anal fistula was reported by three etiologies. Therefore, out of four studies, 12 separate experiments were entered in the meta-analysis. These population-based studies represented 224,097,362 members of the general public. The number of patients with anal fistula in the comprehensive study was 44,722. Table 2 shows the details of the imported articles.

Quality control

The quality of the articles was controlled according to the recommended guidelines of NHLBI (Table 3). None of the studies reported the method of determining the sample size; however, because the number of samples entered was very large and covered a significant population, the researchers determined that this factor did not affect the quality of these four studies. The prevalence of anal fistula was not
evaluate in any of the blinded studies. Lack of blindness also did not affect these studies’ findings, because the report of anal fistula prevalence was mainly based on registry databases. The blindness of the researcher did not affect the classification of individuals as patients or the patients either. None of the four studies reported a drop in patients. The reason for this lack of reporting was the retrospective nature of these studies. Because missing data is commonly mentioned in registry databases, the researchers in these four studies could point out that this is a negative point. As the condition of blinding and determining the sample size did not significantly affect the prevalence of anal fistula, generally, the quality of the articles is in a good range.

**Publication bias**

Begg’s test and funnel plot were used to determine the possible publication bias. Although the Begg’s test showed no publication bias in the present study (p = 0.075), the funnel plot indicated there is a possibility of publication bias (Figure 2). This may be because all of the included studies were related to Europe, and no population-based study in other parts of the world was found. Therefore, the researchers of the present study consider the possibility of publication bias.

**Prevalence of anal fistula**

The overall prevalence of anal fistula in European countries was 18.37 (95% CI: 18.20-18.55%) per 100,000 individuals (Figure 3). No heterogeneity was observed between studies (I² = 0.0%). As shown in Figure 3, the prevalence of anal fistula in the years before 2000 is much lower than in the years after 2000. Therefore, by performing metaregression, it was found that the year of the study (sampling year) is the main cause of heterogeneity between studies (metaregression coefficient = 0.418; p = 0.004) (Figure 4).

![Figure 2. Publication bias between included studies.](image)

**Figure 2.** Publication bias between included studies.

**Prevalence of anal fistula by country studied**

Figure 5 shows the prevalence of anal fistula in different countries. The highest prevalence was reported for Italy (2002, one study) as 23.20 (95% CI: 22.82 to 23.59) per 100,000 people. The prevalence rates of anal fistula in Germany (2002; one study), United Kingdom (2004 and 2014-2017; 5 studies),

![Figure 3. Forest plot the overall prevalence of anal fistula in the general population.](image)

*Prevalence has been reported in the number of cases per 100,000 general population.*

![Figure 4. Prevalence of anal fistula by year of data collection.](image)

**Figure 3.** Forest plot the overall prevalence of anal fistula in the general population.
Prevalence of anal fistulas

Spain (2001, one study), and Finland (1969 to 1978; one study) are shown separately in Table 4.

Discussion

Because epidemiological data on the prevalence of anal fistula is essential to adopting the best strategy for the management and treatment of this complication, for the first time, in this study, a systematic review was performed on the population-based databases in this field. One of the most important findings of the present meta-analysis is that all studies on the prevalence of anal fistula are related to Europe. To date, no study has been conducted in other continents, and this meta-analysis revealed a large knowledge gap in this context. The current findings showed that among 224,097,362 people (the total number of people studied in the existing studies), there were 44,722 cases of anal fistula, and the total prevalence of anal fistula in European countries is 12.81 people per 100,000 people. The highest prevalence of anal fistula was found in Italy. Other systematic reviews in this area, such as the 2019 study by García-a-Olmo et al., have examined studies showing the prevalence of anal fistula in a specific population, such as patients with Crohn's syndrome or trauma (treatment and surgery complications). Their study reported incidence of anal fistula in cryptoglandular infection, trauma, and Crohn's disease is 1.69 per 10,000 people (22). However, the present meta-analysis is the only population-based study that has examined the prevalence of anal fistulas in the general population (not a specific group). One of this study's strengths is its population-based nature, because in epidemiological studies, this component is considered to be the gold standard. Therefore, the systematic review and population-based nature of our study significantly increase the validity of the present study's findings.

One of the limitations of the present study is the lack of existing studies in this field. As there are only four studies in this field, all of which are related to Europe, it is strongly recommended that the prevalence of anal fistula in other parts of the world be investigated to achieve a complete database. Due to the

| Region and recruitment period | Prevalence | 95% confidence interval |
|-------------------------------|------------|------------------------|
| European countries; 1980-1994 | 2.84       | 2.57                   | 3.13 |
| Finland; 1969-1978            | 8.6        | 6.4                    | 11.55 |
| Spain; 2001                   | 10.4       | 9.88                   | 10.95 |
| UK; 2004, and 2014-2017       | 20.76      | 20.06                  | 21.47 |
| Germany; 2002                 | 20.2       | 19.9                   | 20.51 |
| Italy; 2002                   | 23.2       | 22.82                  | 23.6 |

The prevalence is estimated as the number of patients per 100,000 population

Figure 5. Prevalence of anal fistula by study countries. The prevalence is estimated as the number of patients per 100,000 population. Data are reported to be prevalent with a 95% confidence interval.
lack of epidemiological studies in this area, the presence of heterogeneity and publication bias was predictable. Also, because of the retrospective nature of the articles and extraction of data from registry sources with high sample sizes, the lack of blindness and lack of reporting on the method of determining sample size can be ignored. It can be said that heterogeneity is not related to the articles’ quality. Meta-translation in the current study showed that the origin of heterogeneity is the year of study (sampling year), as the prevalence of anal fistula in the years before 2000 is much lower than in the years after 2000. Although being population-based is one of the strengths of epidemiological studies, including the present one, such data sources are always likely to be biased because of inadequate classification or incomplete reporting of diagnostic procedures and processes.

From the present results, it can be estimated that the prevalence of anal fistula in the general European population (not a specific population with a specific disease or complication) is equal to 18.37 per 100,000 people, and the highest prevalence is in Italy. The validity of the present results can be confirmed in part by the population-based nature of this study (224,097,362). The lack of similar data in other parts of the world indicates the urgent need for similar studies in other countries.

Conflict of interests
The authors declare that they have no conflict of interest.

References
1. Sugrue J, Nordenstam J, Abcarian H, Bartholomew A, Schwartz JL, Mellgren A, et al. Pathogenesis and persistence of cryptoglandular anal fistula: a systematic review. Tech Coloproctol 2017; 21:425-32.
2. Parks A, Gordon PH, Hardcastle JD. Pathogenesis and treatment of fistula-in-ano. Br Med J 1961; 1:463.
3. Lo Re G, Berritto D, Verruccio F, Reginelli A, Picone D, Iacobellis F, et al. Anal Fistula in Crohn’s Disease. In: Lo Re G, Midiri M, Eds. Crohn’s Disease. New York:: Springer International Publishing; 2016: P.115-26.
4. Zanotti C, Martinez-Puente C, Pascual I, Pascual M, Herreros D, García-Olmo D. An assessment of the incidence of fistula-in-ano in four countries of the European Union. Int J Colorectal Dis 2007; 22:1459-1462.
5. Srivastava K, Agarwal A. A complex fistula-in-ano presenting as a soft tissue tumor. Int J Surg Case Rep 2014; 5:298-301.
6. Marzo M, Felice C, Pugliese D, Andrisani G, Mocci G, Armuzzi A, et al. Management of perianal fistulas in Crohn’s disease: an up-to-date review. World J Gastroenterol 2015; 21:1394.
7. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, Rennie D, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000; 283:2008-2012.
8. Hassanazadeh-Rad A, Yousefifard M, Katal S, Asady H, Fard Esfahani A, Moghadas Jafari A, et al. The value of 18F-fluorodeoxyglucose positron emission tomography for prediction of treatment response in gastrointestinal stromal tumors: a systematic review and meta-analysis. J Gastroenterol Hepatol 2016; 31:929-935.
9. Yousefifard M, Baikpour M, Ghelichkhani P, Asady H, Nia KS, Jafari AM, et al. Screening performance characteristic of ultrasonography and radiography in detection of pleural effusion; a meta-analysis. Emergency 2016; 4:1.
10. Hosseini M, Yousefifard M, Aziznejad H, Nasirinezhad F. The effect of bone marrow-derived mesenchymal stem cell transplantation on allodynia and hyperalgesia in neuropathic animals: a systematic review with meta-analysis. Biol Blood Marrow Transplant 2015; 21:1537-1544.
11. Hosseini M, Ghelichkhani P, Baikpour M, Tafakhori A, Asady H, Ghanbari MJH, et al. Diagnostic accuracy of ultrasonography and radiography in detection of pulmonary contusion; a systematic review and meta-analysis. Emergency 2015; 3:127.
12. Hosseini M, Yousefifard M, Baikpour M, Rahimi-Movaghar V, Nasirinezhad F, Younesian S, et al. The efficacy of Schwann cell transplantation on motor function recovery after spinal cord injuries in animal models: a systematic review and meta-analysis. J Chem Neuroanatomy 2016;102:78-111.
13. Ebrahimi A, Yousefifard M, Kazemi HM, Rasouli HR, Asady H, Jafari AM, et al. Diagnostic accuracy of chest ultrasonography versus chest radiography for identification of pneumothorax: a systematic review and meta-analysis. Tanaffos 2014; 13:29.
14. Yousefifard M, Rahimi-Movaghar V, Nasirinezhad F, Baikpour M, Safari S, Saadat S, et al. Neural stem/progenitor cell transplantation for spinal cord injury treatment; a systematic review and meta-analysis. Neuroscience 2016; 322:377-397.
15. Nasirinezhad F, Hosseini M, Karami Z, Yousefifard M, Janzadeh A. Spinal 5-HT3 receptor mediates nociceptive effect on central neuropathic pain, possible therapeutic role for tropisetron. J Spinal Cord Med 2016; 39:212-219.
16. Rahimi-Movaghar V, Yousefifard M, Ghelichkhani P, Baikpour M, Tafakhori A, Asady H, et al. Application of ultrasonography and radiography in detection of hemothorax;
8 Prevalence of anal fistulas

a systematic review and meta-analysis. Emergency 2016; 4:116.

17. Moher D, Liberati A, Tetzlaff J, Altman D. Academia and clinic annals of internal medicine preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Ann Intern Med 2009;151: 264–69.

18. Quality Assessment Tool for Observational Case-Control Studies. Available from: https://www.nhlbi.nih.gov/health-topics/study-quality-assessment-tools.

19. Cuschieri A, Group EW. Descriptive epidemiology of isolated anal anomalies: a survey of 4.6 million births in Europe. American journal of medical genetics 2001; 103:207-15.

20. Sainio P. Fistula-in-ano in a defined population. Incidence and epidemiological aspects. Ann Chir Gynaecol 1984;73:219-24.

21. Hokkanen SR, Boxall N, Khalid JM, Bennett D, Patel H. Prevalence of anal fistula in the United Kingdom. World J Clin Cases 2019; 7:1795.

22. García-Olmo D, Van Assche G, Tagarro I, Diez MC, Richard MP, Khalid JM, et al. Prevalence of Anal Fistulas in Europe: Systematic Literature Reviews and Population-Based Database Analysis. Adv Ther 2019; 36:3503-18.